09:49 AM EST - ProMetic Life Sciences Inc. : Reported that it had been approved to commence the clinical trial of its orally active anti-fibrotic lead drug candidate, PBI-4050, in patients suffering from cystic fibrosis, following the CTA clearance by Health Canada. The objectives of this 24 week randomized, double-blind, and placebo-controlled Phase 2 study includes the evaluation of the effects of PBI-4050 on pancreatic and lung function in 90 CF patients. ProMetic Life Sciences Inc.
shares T.PLI are trading up $0.03 at $3.04.
